Shree Ganesh Remedies Ltd. · BSE:SGRL
Shree Ganesh Remedies — Q3 FY25 Earnings Presentation
36 slides from Shree Ganesh Remedies's earnings presentation, Feb 5, 2025
Slide 1: Investor Presentation filing letter to BSE
February 05, 2025 To, Listing Department BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Fort Mumbai - 400001 Script Code – 540737 Sub: Investor Presentation With reference to the captioned subject, we enclose herewith the Investor Presentation with respect to Unaudited Financial Results of the
Slide 2: Investor Presentation Q3 & 9MFY25
Investor Presentation Q3 & 9MFY25 Innovate. React. Transform.
Slide 3: Inside the Presentation
Inside the Presentation Financial Highlights 22 5 Year Summary 23 Key Ratios Forward Looking 24 P&L Summary Statement About the Business 25 Balance Sheet Summary In so far as forecasts or expectations are expressed 04 Excellence in Complex Chemistry 26 Cash Flow Summary in this presentation or where
Slide 4: About the Business
About the Business Excellence in Complex Chemistry 04 Unparalleled Expertise in Advanced Chemical Synthesis 05 Unmatched Technology Prowess In Complex Chemical Reactions 07 Tailored Solutions Through Mastered Chemistry and Technology 08 Strategic Product Selection Criteria 09 Our Evolving Business M
Slide 5: Excellence in Complex Chemistry
ABOUT THE COMPANY Excellence in Complex Chemistry Established Expertise Strategic Expansions Over 19 years of excellence in chemical Continuous investments in new manufacturing manufacturing, specialising in pharmaceutical blocks and R&D centers to enhance production intermediates and speciality che
Slide 6: Unparalleled Expertise in Advanced Chemical Synthesis
ABOUT THE COMPANY Unparalleled Core Strengths in Mastered Chemistries Expertise in Our company excels in the following core chemistries, with dedicated manufacturing blocks for each: Advanced 1. Halogenation Chemical • Chlorination: Using Thionyl Chloride, Sulphuryl Chloride, Oxalyl Chloride, Mesyl
Slide 7: Unparalleled Expertise in Advanced Chemical Synthesis (Continued)
ABOUT THE COMPANY Unparalleled Expertise in Advanced Chemical Synthesis (Continued) Additional Chemistries Other Reaction Capabilities While we currently do not have dedicated Heterocycle Synthesis 1 blocks for the following chemistries, we have Nitration 2 established a strong foothold and are eval
Slide 8: Unmatched Technology Prowess In Complex Chemical Reactions
ABOUT THE COMPANY Unmatched Technology Prowess Key Technological Capabilities In Complex Liquid-Gas Reaction: Expertise in managing reactions involving both liquid and 1 Chemical gas phases, ensuring optimal reaction conditions and high yields. High-Pressure Reaction: Proficiency in conducting react
Slide 9: Tailored Solutions Through Mastered Chemistry and Technology
ABOUT THE COMPANY Tailored Solutions Through Mastered Chemistry and Technology Products by chemistry Industries Catered Chloro-Alkyl Amines HCl Salts Human and Veterinary Health Cyclopropane Derivatives Cyclobutane Derivatives Agrochemical Industry Carboxylic Acids & Acid Chlorides Aliphatic Chlorid
Slide 10: Strategic Product Selection Criteria
ABOUT THE COMPANY Strategic Product Chemistry Skillset The product must fall Technology Skillset Selection Margin Profile within the chemistry skills we have mastered. We must be capable of The product must meet our handling the complex internal benchmarks for processes involved, or we Criteria sust
Slide 11: Our Evolving Business Model
ABOUT THE COMPANY Our Evolving Business Model Inception Inception Pharmaceutical Intermediates Speciality and Fine Chemicals Since Company’s inception in 2004 Entered in 2010 Focus Focus Intermediates for Off-patent and generic drugs Moving towards patented molecules requiring strong technical know
Slide 12: Collaborating With Industry Leaders
ABOUT THE COMPANY Collaborating With Industry Leaders 11 Shree Ganesh Remedies Limited
Slide 13: Ankleshwar Site Expansion Fuelling Our Growth Strategy
ABOUT THE COMPANY Ankleshwar Site Unit 2 Expansion Fuelling We also have a unit 2 at Ankleshwar which has 2 functional blocks. Our Growth Strategy Unit 1 Production Blocks • Currently 7 functional blocks • Block 8 added in FY24 • CAPEX for Block 8: ₹ 15 crores Additional Land Acquisition - Unit 1 •
Slide 14: Infrastructure at Ankleshwar Site
ABOUT THE COMPANY Infrastructure at Ankleshwar Site 35 28 Glass Lined Reactors Stainless Steel Reactors 1000 to 25,000 Ltr 1000 to 15,000 Ltr *2 cryogenic (-30 Deg C) *1 cryogenic (-40 Deg C) 3 9 8 4 Autoclave Reactors Dryers Distillation Setup Warehouse 2000 Ltr 1000 to 2,500 Ltr Upto 50 Stages Upt
Slide 15: Dahej Land Acquisition Setting the Stage for Large Scale Projects
ABOUT THE COMPANY Dahej Land Acquisition Setting the Stage for Large Scale Projects Site Development • Fencing and ground levelling work already commenced Land Expansion Strategic Use Acquired 40,554 sq m land • Dahej site to host projects with large corporates for custom product requirements at lar
Slide 16: Driving Innovation Through Strategic R&D Investments
ABOUT THE COMPANY Driving Innovation R&D Lab Recognition Through Strategic Recognised by DSIR (Department of Scientific and Industrial Research), Central Government R&D Investments R&D and Process Team Composition 40 Total Team Members Global Expansion Exploring the setup of R&D facilities in foreig
Slide 17: State-of-the-Art R&D Infrastructure
ABOUT THE COMPANY State-of-the-Art R&D Infrastructure Key Facilities Advanced Analytical Labs Equipped with cutting-edge instruments for precise analysis Pilot Plants For scale-up studies and process optimisation Dedicated Synthesis Labs For novel compound development High-Performance Computing (HPC
Slide 18: Accreditations that Speak to Our Comprehensive Standards
ABOUT THE COMPANY Accreditations that Speak to Our Comprehensive Standards Indian GMP Certified ISO 9001:2015 Certified ISO 14001:2015 Certified ISO 45001:2018 Manufacturing Facility (Bureau Veritas) (Bureau Veritas) Certified (CCPL) DSIR Recognised Bronze Certified by Halal In-house R&D Lab EcoVadi
Slide 19: Driving Innovation and Growth
ABOUT THE COMPANY Driving Innovation and Growth Chandu Kothia Gunjan Kothia Parth Kothia Founding Promoter, Promoter, Promoter, Managing Director Whole Time Director Whole Time Director, CFO Qualifications: Master of Pharmacy Qualifications: BE in Chemical Engineering Qualifications: BTech in Chemic
Slide 20: Ensuring Health and Safety
ABOUT THE COMPANY Ensuring Health and Safety Technical Personal Protection Organisational Health Measures Equipment Measures Check Closed charging and Working clothes with HAZOP compatible study Regular health check-ups discharging systems glasses and gloves on raw materials and finished products He
Slide 21: Protecting the Environment With Sustainable Practices
ABOUT THE COMPANY Protecting the Environment With Sustainable Practices Conversion of flue In-house wastewater High-temperature Biological gases to by-products treatment for incinerator for wastewater for environmental recycling of water toxic waste treatment plant protection 20 Shree Ganesh Remedie
Slide 22: Financial Highlights
Financial Highlights 5 Year Summary 22 Key Ratios 23 P&L Summary 24 Balance Sheet Summary 25 Cash Flow Summary 26 02
Slide 23: 5 Year Summary
FINANCIAL HIGHLIGHTS 5 Year Summary Revenue from Operations Profit After Tax EBITDA & EBITDA Margins EPS (₹ IN CRORES) (₹ IN CRORES) (₹ IN CRORES & IN %) (IN ₹) 31% 33.2% 25 21% 45.00 35.0% CAGR 27.8% 25.7% 22.35 41.81 40.00 28.12 CAGR 30.0% 125.90 25.1% 20 35.00 25.0% 30.00 18.7% 15 20.0% 25.00 20.
Slide 24: Key Ratios
FINANCIAL HIGHLIGHTS Key Ratios ROE ROCE Equity & Debt to Equity Ratio Cash from Operating Activities (IN %) (IN %) (₹ IN CRORES & IN TIMES) (₹ IN CRORES) 122.11 0.38 35 140.00 0.40 30 0.35 30.45 120.00 23.0% 0.30 25 100.00 25.5% 61.57 0.25 20 0.26 87.20 80.00 50.00 0.20 42.10 15 60.00 0.15 10 40.00
Slide 25: P&L Summary
FINANCIAL HIGHLIGHTS P&L Summary CAGR 21% 40% 31% (FY20-24) Revenue EBITDA PAT PARTICULARS ( ₹ I N C R O R E S ) FY20 FY21 FY22 FY23 FY24 Revenue from Operations 58.43 49.08 71.29 91.36 125.90 Total Income 62.60 51.18 74.86 92.07 128.96 Operating Expenses 47.48 35.43 53.37 67.92 84.09 EBITDA (Exclud
Slide 26: Balance Sheet Summary
FINANCIAL HIGHLIGHTS Balance Sheet Summary PARTICULARS ( ₹ I N C R O R E S ) FY20 FY21 FY22 FY23 FY24 Shareholders' Funds 42.10 50.00 61.57 87.20 122.11 Non-Current Liabilities 0.49 0.41 0.40 30.66 30.16 Long Term Borrowings 0.04 0.00 0.00 30.44 29.12 Current Liabilities 9.67 10.19 15.04 20.11 18.68
Slide 27: Cash Flow Summary
FINANCIAL HIGHLIGHTS Cash Flow Summary PARTICULARS (₹ IN CRORES) FY20 FY21 FY22 FY23 FY24 Cash from Operating Activities 3.88 3.31 13.42 17.10 30.45 Cash from Investing Activities (2.91) (0.94) (11.91) (51.09) (33.09) Cash from Financing Activities (0.21) (0.66) (1.09) 38.66 9.85 Net Cash Flow 0.76
Slide 28: Investment Merits
Investment Merits Investment Case 28 03
Slide 29: Investment Case
INVESTMENT MERITS Investment Case Lean Balance Experienced Increasing Focus Available Land for Humongous Sheet: Management at on Complex Further Capacity Addressable The company the Helm: Molecules and Expansions: Opportunity Size: maintains a strong Led by a seasoned Niche Specialty With ample land
Slide 30: Quarterly Highlights
Quarterly Highlights Management Commentary 30 P&L Summary 31 Balance Sheet Summary 32 Cash Flow Summary 33 04
Slide 31: Management Commentary
QUARTERLY HIGHLIGHTS Management Commentary I am pleased to share our performance update for Furthermore, I am pleased to announce that the Q3FY25. In this quarter, we experienced a decline designing phase of Block 7 has been completed, in revenue due to intensified domestic and construction activiti
Slide 32: P&L Summary
QUARTERLY HIGHLIGHTS P&L Summary YoY Change -3% 21% 13% Revenue EBITDA PAT YoY QoQ YoY PARTICULARS ( ₹ I N C R O R E S ) Q3FY24 Q2FY25 Q3FY25 9MFY24 9MFY25 Change Change Change Revenue from Operations 27.97 32.33 27.05 -3% -16% 88.11 84.16 -4% Total Income 29.09 32.52 27.76 -5% -15% 90.58 85.61 -5%
Slide 33: Balance Sheet Summary
QUARTERLY HIGHLIGHTS Balance Sheet Summary PARTICULARS ( ₹ I N C R O R E S ) FY24 H1FY25 Shareholders' Funds 122.11 133.16 Non-Current Liabilities 30.16 27.80 Long Term Borrowings 29.12 26.65 Current Liabilities 18.68 17.37 Short Term Borrowings 7.19 7.05 Trade Payables 8.19 8.87 Total Equity and Li
Slide 34: Cash Flow Summary
QUARTERLY HIGHLIGHTS Cash Flow Summary PARTICULARS (₹ IN CRORES) H1FY24 H1FY25 Cash from Operating Activities 6.54 13.64 Cash from Investing Activities -9.49 -10.35 Cash from Financing Activities 1.60 -4.90 Net Cash Flow -1.36 -1.61 Cash at the Beginning of Year 8.65 16.20 Cash at the End of Year 7.
Slide 35: Market Statistics
Market Statistics Shareholding Pattern CURRENT MARKET PRICE ₹ 837.65 52 WEEK HIGH/LOW ₹ 950.05 / 557.95 MARKET CAPITALIZATION ₹ 1,075.12 Cr SHARES OUTSTANDING 1.28 Cr Promoter 72.80% BSE SCRIP CODE 540737 Public 27.20% Shareholding Data as on 31st December 2024 Market Price Data as on 5th February 2
Slide 36: Contact Us
Contact Us Shree Ganesh Remedies Limited Headquarters: Plot No. 6002, 6003, 6011 & 6012, GIDC Estate, Ankleshwar, Gujarat India – 393002 Aditya Patel Abhishek Mehra Company Secretary Investor Relations Advisors Shree Ganesh Remedies Limited TIL Advisors Private Limited [email protected] a
Shree Ganesh Remedies — Q3 FY25 Earnings Presentation on 6ix